On the other hand, it has been reported that 6 and 12 months of imatinib treatment did not create a significant difference in MDR1 levels in different cell populations of CML patients between pre-treatment and post-treatment. This evidence concerns the gene ABCB1 and chronic myelogenous leukemia, BCR-ABL1 positive.